Oral compositions and the preparation methods thereof

ABSTRACT

The present invention relates to a process for preparing a solid composition comprising at least one active ingredient and at least one excipient comprising: i) mixing said at least one active ingredient and said at least one excipient in a granulator to obtain wet granules; ii) spreading wet granules on a tray and let stand for 2 to 24 hours between 15 and 25° C.; iii) compressing granules obtained after step ii) with a tablet press; and iv) collecting the solid composition. The invention further relates a solid composition obtained by such process.

FIELD OF THE INVENTION

The present invention relates to the veterinary field. Moreparticularly, the invention concerns the preparation of compositions fortherapeutic purposes, which are formulated in solid form to beadministered to animals, more particularly to improve oraladministration and to guarantee treatment compliance.

BACKGROUND OF THE INVENTION

Oral route is currently the priority route for administering medicationsby health professionals or owners to animals and typically to domesticanimals. Indeed, the parenteral route (intramuscular, sub-cutaneous,intradermal, and intravenous) has a number of drawbacks. This parenteralroute may cause hematomas and abscesses for the animal and oftenrequires a specialist. Such parenteral route for administeringmedication is thus not pleasant for the animal and quite constrainingfor the owner.

However, pharmaceutical or nutraceutical compositions administered byoral route are not always well accepted by the animal and it is wellknown that acceptation is based on main properties of such compositions,for instance palatability, texture, shape, and size. In addition tothese parameters, it is crucial to fully control the quantity of theactive ingredient(s) in the composition and, preferably, prepare suchcompositions with a lowest cost.

It exists a large number of commercially available oral formulations.Such formulations are for instance tablets, pills, hard capsules, softcapsules, chewable gums or soft chews, and pellets. However, it haschiefly been ascertained that treatment via oral route with solidformulations is not always properly followed on account of thedifficulty in administering a full treatment in animals, reducingthereby its compliance. Indeed, the oral administration of solidcompositions to animals is often difficult on account of the bad tasteof some active ingredients and excipients and the much developed senseof smell and taste in animals. It has thus been observed in animals thatthe main reason which makes it difficult even impossible to properlyfollow oral treatment is the lack of palatability of the solidcomposition.

The palatability of a solid composition administered by oral routecorresponds to the acceptance and voluntary ingestion thereof by ananimal. The palatability depends on different characteristics of thesolid composition. For instance, the taste is a crucial parameter for animproved palatability and a lot of flavors or palatable materials areadded in the solid compositions. The texture of the solid compositioncharacterized by hardness, brittleness, softness, elasticity, color havefurther to be considered. Also, the shape and the size of the solidcomposition may facilitate the acceptation of the solid composition bythe animal.

In this context, soft chews have been developed and manufacturedaccording to two major processes, which are a process with forming and aprocess with extrusion.

The process with forming comprises a first step of blending ingredientsto form a soft dough, which is then molded in a specifically definedmold without compression or heat, using a forming machine such asmachine type Formax F6. Such process is more particularly disclosed bythe following applications: WO 2009/06485 and WO 2012/049156 in the nameof Bayer, WO 2014/079825 in the name of Intervet and for which the doughis heated between 35 and 45° C., and WO 2013/119442 in the name ofMerial. However, the process with forming requires a long step ofmaturation after demolding at room temperature or in a stove in order toharden the soft chew tablet so that they can be more easily handled andpackaged.

The process with extrusion requires a screw, wherein mixed ingredientsare pushed through an orifice and cut to a specific size by blades. Suchprocess also requires a control of pressure and temperature. Thisprocess is more particularly disclosed in the following applications WO2005/013714 in the name of Novartis and WO 2008/134819 in the name ofJurox, for which the extrudate is cut into equal piece.

The processes with forming and with extrusion allow to manufacture softchewable compositions in a unique shape and a unique size only. Indeed,it is required to define a shot size in the process with extrusion,which is not always very accurate, and a specific mold is required forthe process with forming. In addition, the soft chewable compositionsobtained by such processes have to be hardened thanks to a longmaturation step but still stay friable when they are handled and packed.Another drawback is that the active ingredient(s) is not homogenouslydispersed, which is not suitable for a good compliance of the treatment.

Friulchem SPA has developed a process for preparing soft chews. Thisprocess is disclosed by the international application WO 2013/037650 andprovides the soft chew “FC-CUBES”. The process of Friulchem SPAcomprises a step of mixing dry and liquid components followed by agranulation step by vaporizing animal or vegetable fats. Granules arethen directly calibrated and compressed with a special stock cube pressto give the soft chew “FC-CUBES”, which are rather palatable thanks tohigh proportion of palatable ingredients used including fats andflavors. However, the “FC-CUBES” must be administrated in whole into theanimal since it cannot be bi- or quadrisected depending on the weight ofthe animal because of the high proportion of fat ingredients. Also, theprocess of Friulchem SPA allows to obtain a soft chew in a unique shapeaccording to the press used.

In view of the above, there is still a need to develop new processes forthe manufacture of solid compositions intended to be administered by anoral route in an animal while guarantying and improving treatmentcompliance.

SUMMARY OF THE INVENTION

In this context, the inventors have surprisingly implemented a processfor preparing a solid composition allowing to obtain a new oral dosageform improving the treatment compliance. Such process, particularlycomprising a step of spreading of wet granules at room temperature,provides a solid composition in an intermediate form between usualtablets and soft chewable formulations, and can be named “soft tablet”.The term “soft tablet” as disclosed herein thus refers to a solidcomposition obtained by the process of the invention using a tabletpress.

The solid composition or “soft tablet” prepared by the process asdisclosed herein is suitable for any active ingredients to be orallyadministered in an animal and exhibit major advantages compared to theclassic soft chew and tablet formulations. More particularly, the “softtablet” comprises at least one active ingredient, which is morehomogenously dispersed compared to the active ingredient(s) comprised inthe classic soft chewable formulations. The “soft tablet” is also notsticky and is easier to handle and package than the soft chew. The “softtablet” can further be bi- or quadrisected, as classic tablet forms. Ithas also the advantage of being manufactured in many possible shapesthanks to the use of classic tablet press. Production costs are alsosignificantly reduced when compared to processes of the prior art sincethe process according to the present invention is as fast as forconventional tablet production. Therefore, the process as disclosedherein does not necessitate an elaborate and costly equipment, andprovides “soft tablets” having both the advantages of classic soft chewand tablet formulations.

The present invention therefore relates to a process for preparing asolid composition comprising at least one active ingredient, and atleast one excipient, wherein the process comprises the followingsuccessive steps:

-   -   i) mixing said at least one active ingredient and said at least        one excipient in a granulator to obtain wet granules;    -   ii) spreading the obtained wet granules on a tray and let stand        for 2 to 24 hours between 15 and 25° C.;    -   iii) compressing granules obtained after step ii) with a tablet        press; and    -   iv) collecting the solid composition.

In a first embodiment, said solid composition comprises at least oneactive ingredient chosen from among anti-infectives such as antibioticsand sulfonamides, cardiotonics, internal and external anti-parasitics,insecticides, insect growth inhibitors, anti-arthritics,anti-inflammatories whether or not steroidal, anti-histaminics, hormonessuch as prostaglandins, substances for digestive therapy such asgastro-intestinal dressings and sedatives, anti-ulcer agents andsubstitution flora, anti-diarrhoeals, hepato-protectors, antispasmodics,laxatives, intestinal antiseptics, substances for respiratory therapysuch as respiratory analeptics, antitussives, bronchodilators, bronchialand mucolytic fluidifiers and respiratory antiseptics, substances actingon the nervous system such as analgesics, sedatives and tranquillizers,anti-epileptics, anaesthetics, orexigenics, anorexigenics, substancesfor immunity therapy such as interleukins and interferon, substances foranticancer therapy such as antimitotics and cytostatics, macro-,micro-nutrients and trace elements, vitamins, plant extracts, extractsfrom animal organs, and a mixture thereof.

In a second embodiment, said solid composition comprises at least oneactive ingredient chosen from among an active nutraceutical or a foodsupplement ingredient, preferably chosen from among plant extracts,animal extracts, substitution flora, macro-, micro-nutrients andtrace-elements, and a mixture thereof.

In a particular embodiment, said solid composition comprises at leastone excipient chosen from among a palatable material, a humectant, abinder, a lubricant, a filler, a disintegrant, and a mixture thereof.

In a preferred embodiment, said solid composition comprises:

-   -   between 0.01 and 20.00%, preferably between 1.00 and 10% by        weight of said at least one active ingredient,    -   between 15.00 and 30.00%, preferably about 20.00% by weight of        said at least one palatable material,    -   between 15.00 and 35.00%, preferably between 20.00 and 30.00% by        weight of said at least one humectant,    -   between 20.00 and 40.00%, preferably about 24.50% by weight of        said at least one binder,    -   between 0.10 and 10.00%, preferably about 5.00% by weight of        said at least one lubricant,    -   between 10.00 and 30.00%, preferably between 15.00 and 25.00% by        weight of said at least one filler, and    -   between 0.10 and 10.00%, preferably about 4.00% by weight of        said at least one disintegrant, relative to the total weight of        the solid composition.

In a particular embodiment, said solid composition further comprises atleast one preservative and/or at least one antioxidant, and/or at leastone chelating agent.

In a preferred embodiment, the present invention relates to a processcomprising the following successive steps:

-   -   i) a) mixing said at least one active ingredient, said at least        one palatable material, said at least one binder, said at least        one filler, said at least one lubricant, and said at least one        disintegrant in a granulator;    -   i) b) spraying said at least one humectant onto the blend of        step i) a) and mixing to obtain wet granules;    -   ii) a) spreading the wet granules obtained after step i) b) and        let stand for 2 to 24 hours between 15 and 25° C.;    -   ii) b) milling the granules obtained after step ii) a) with an        oscillating granulator, and then sifted, through a 800 to 2000        μm sieve, preferably through a 1250 μm sieve;    -   ii) c) optionally letting stand the granules for 2 to 24 hours        at room temperature;    -   iii) a) optionally blending the granules obtained after        step ii) b) or step ii) c) with at least one disintegrant and/or        at least one filler in a blender.    -   iii) b) blending the granules obtained after step ii) b), ii) c)        or iii) a) with at least one lubricant in a blender;    -   iii) c) compressing the blend obtained after step iii) b) with a        tablet press; and    -   iv) collecting the solid composition.

Another objet of the invention is a solid composition obtained by theprocess as disclosed herein.

LEGEND TO THE FIGURES

FIG. 1 : Picture of a quadrisected “soft tablet” obtained by the processof the invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention herein provides a process for preparing a solidcomposition comprising at least one active ingredient, and at least oneexcipient, wherein the process comprises the following successive steps:

-   -   i) mixing said at least one active ingredient and said at least        one excipient in a granulator to obtain wet granules;    -   ii) spreading wet granules on a tray and let stand for 2 to 24        hours between 15 and 25° C.;    -   iii) compressing granules obtained after step ii) with a tablet        press; and    -   iv) collecting the solid composition.

The present invention further provides a solid composition obtained bythe process as disclosed herein.

Solid Composition

The solid composition obtained by the process according to the inventioncan be considered as an intermediate form between classic tablets andsoft chews and corresponds to a “soft tablet”.

Such “soft tablets” comprise at least one active ingredient homogenouslydispersed and accurately dosed, and at least one excipient. By “activeingredient” is meant an ingredient of a medicinal product, anutraceutical or food supplement having a therapeutic effect or abiological activity, or also a non-therapeutic effect.

Contrary to the classic soft chews, the “soft tablets” are not sticky,not friable and hard enough to be manipulated and packaged. Also, theycan be bi- or quadrisected according to the type, the size, and theweight of the animal for which the “soft tablets” are orallyadministered, and can be in various shapes according to the mold used inthe press tablet. For instance, the “soft tablets” can be in a circular,oval, cube, square, triangular, clover form, and any other formaccording to the mold used. Also, the “soft tablets” can be obtained inseveral sizes. In a circular form, the diameter of the “soft tablets”may vary between 5 and 30 mm, 5 and 25 mm, 5 and 20 mm, 5 and 15 mm,preferably between 10 and 15 mm. More preferably, the diameter of the“soft tablets” is about 14 mm. The own properties of the “soft tablets”according to the invention satisfy the requirements of the parametersfor an improved observance of the treatment applied in an animal.

Contrary to the classic tablets, “soft tablets” hardness cannot bemeasured by classic equipment because of its softness. The conventionalprocess to evaluate tablet hardness is compression testing whereby theanalyst generally aligns the tablet in a repeatable way, and the tabletis squeezed by 2 jaws. A continuous force is applied with a spring andscrew thread until the tablet starts to break. When the tabletfractures, the hardness is read with a sliding scale. However, in thecase of the soft tablets according to the present invention, the softtablet bends and the force is zero.

The solid compositions or “softs tablets” of the invention are suitablefor any treatments orally administered to an animal and a skilled personcan chose the quantity and the nature of the at least one activeingredient according to the biological effect he wishes to obtain.

For instance, the at least one active ingredient is chosen from amonganti-infectives such as antibiotics and sulfonamides, cardiotonics,internal and external anti-parasitics, insecticides, insect growthinhibitors, anti-arthritics, anti-inflammatories whether or notsteroidal, anti-histaminics, hormones such as prostaglandins, substancesfor digestive therapy such as gastro-intestinal dressings and sedatives,anti-ulcer agents and substitution flora, anti-diarrhoeals,hepato-protectors, antispasmodics, laxatives, intestinal antiseptics,substances for respiratory therapy such as respiratory analeptics,antitussives, bronchodilators, bronchial and mucolytic fluidifiers andrespiratory antiseptics, substances acting on the nervous system such asanalgesics, sedatives and tranquillizers, anti-epileptics, anaesthetics,orexigenics, anorexigenics, substances for immunity therapy such asinterleukins and interferon, substances for anticancer therapy such asantimitotics and cytostatics, macro-, micro-nutrients and traceelements, vitamins, plant extracts, extracts from animal organs, and amixture thereof.

Preferably, the at least one active ingredient is a substance having arepulsive odor and/or or taste. These are for example aldosteroneantagonists, angiotensin conversion enzyme inhibitors, antagonists ofthe AT-1 receptor of angiotensin II, inotropic agents, inodilators,vasodilators, diuretics, digitalis drugs, beta blockers and/or calciumantagonists. The process is also advantageous when said pharmaceuticalactive substances are unstable and sensitive to moisture.

Among the aldosterone antagonists, spironolactone and eplerenone, or themetabolites of these compounds, which among others include canrenone,canrenoic acid, 1513-0H canrenone, 21-0H canrenone, potassium canrenone,7α-thio-spironolactone, 7α-thiomethyl-spironolactoneor6-β-hydroxy-7-α-thiomethyl spironolactone may be mentioned.

Among the angiotensin conversion enzyme inhibitors, alacepril,benazepril, captopril, cilazapril, delapril, enalapril, fosinopril,imidapril, idrapril, lisinopril, perindopril, quinapril, ramipril,saralasin acetate, termocapril, trandolapril, ceranapril, moexipril,spirapril and their pharmaceutically acceptable derivatives of thesecompounds such as in particular the salts and esters may be mentioned.

Among the inodilators, pimobendane or levosimendane may be mentioned.

In a preferred embodiment, the at least one active ingredient isspironolactone and/or benazepril and/or enalapril.

The solid compositions as disclosed herein are particularly useful fortreating non-human animals suffering from cardiac insufficiency such ascongenital cardiopathy or acquired cardiopathy as described inparticular in the international publication WO 2009/000843. Also, anobject of the present invention is a solid veterinary composition asdisclosed herein, for use thereof in the treatment and/or the preventionof cardiac insufficiency in non-human animals.

A further object of the present invention is a method for treatingand/or preventing cardiac insufficiency in a non-human animal,comprising administering a solid veterinary composition as disclosedherein in a non-human animal.

A further object of the present invention is a use of a solid veterinarycomposition as disclosed herein for the manufacture of a drug fortreating and/or preventing cardiac insufficiency in a non-human animal.

Thus, the solid veterinary composition according to the presentinvention can, for example, comprises a therapeutically effective dailydose of an aldosterone receptor antagonist such as spironolactone and/orderivatives or metabolites thereof of between about 0.88 and 5.00mg/kg/day (preferably about 2.00 mg/kg/day) and a dose of an angiotensinconversion enzyme inhibitor, such as benazepril, of between 0.10 to 0.60mg/kg/day (preferably about 0.25 mg/kg/day).

Other active ingredients are for example compounds having antiparasiticactivity against endoparasites and/or ectoparasites. These includewithout limitation the macrocyclic lactones: avermectins and milbemycinssuch as preferably ivermectin, eprinomectin, selamectin, moxidectin andmilbemycin oxime, benzimidazoles, imidazothiazoles,tetrahydropyrimidines, organophosphates, piperazines, antimicrobialagents or also antibiotic agents such as preferably amoxicillin.

Other active ingredients may be selected from organosulfur compoundssuch as omeprazole, aiming to reduce the acid secretions of the stomach.

In a further preferred embodiment, the solid veterinary compositionaccording to the present invention comprises milbemycin, milbemycinoxyme, both milbemycin oxyme and praziquantel, praziquantel, lufenuron,ivermectin, both ivermectin and pyrantel, lufenuron, levamizole,doxycycline or a dog appeasing pheromone.

The “softs tablets” of the invention are further suitable for any oraltreatments intended to improve the welfare of the animal. In thiscontext, the “soft tablet” comprises at least one active ingredientchosen from among an active nutraceutical and a food supplementingredient. Particularly, the active nutraceutical or the foodsupplement ingredient is chosen from among extracts for theiranti-arthritic action such as chondroitin sulfate, chitosan and itsderivatives S-Adenosyl Methionine (SAMe), for their anti-ulcer and/oranti-stress action such as fermented soy extract, for their insecticidalor insect repellent action such as pyrethrums, vitamins such a vitaminC, vitamin D3, substitution flora such as Enterococcus faecium,micro-nutrients such as selenium provided by a strain of Saccharomycescerevisiae, for their appeasing effect such as appeasing pheromonese.g.: Adaptil. Preferably, the active nutraceutical or the foodsupplement ingredient is chosen from among plant extracts, animalextracts, substitution flora, macro-, micro-nutrients andtrace-elements, and a mixture thereof.

The solid compositions or “soft tablets” of the invention furthercomprise at least one excipient and, notably, a mixture of particularexcipients providing the desired properties of the “soft tablets”. Theat least one excipient can be chosen from among a palatable material, ahumectant, a binder, a lubricant, a filler, a disintegrant, and amixture thereof.

The palatable material provides a taste and an odor for the soft tablet,which is thus more accepted by the animal and thereby improving thecompliance. The palatable material can be sweet and/or can derived frommeat ingredients, or any natural, natural identical or artificialflavoring substances. It also comprises flavors such as essential oils,terpene derivatives (menthol), franeol, test enhancers such as sodiumglutamate, sweeteners such as aspartame, sodium saccharin, maltol,polyols such as sorbitol, isomalt, maltitol, mannitol, and lactitol. Ina preferred embodiment, the “soft tablet” comprises without limitationat least one palatable chosen from among meat, meat powders, fishpowders, cheese powders, milk derivatives, liver powder, the extracts ofthese animal substances or their derivatives, yeasts, yeast extractssuch as beer yeast, vegetable fibers, vegetable products and by-productssuch as malt extracts, fenugreek, apple, carrot, fodder beet, sugarbeet, thyme, alfalfa, sugar cane, cereals such as oats, wheat, rice,corn, soy, their derivatives such as flours and a mixture thereof,crystallized sugar, powder sugar glucose, invert sugar, molasses,caramel, honey and its derivatives, sodium chloride, and a mixturethereof. In a preferred embodiment, the palatable material is a pigliver powder, a chicken liver flavor, a chicken flavor, yeast extract,malt extract, and a mixture thereof.

The humectant, the binder, the lubricant, the filler, and thedisintegrant provides the specific physical properties of the “softtablets” such as a hardening suitable for a good breakability, afriability suitable for a good handling and packaging, and a soft aspectfor being manufactured in a non-limited shape number.

In a preferred embodiment, the humectant is chosen from among propyleneglycol, glycerin, sorbitol, polyethylene glycol, and liquid oils such assoya bean oil, peanut oil, olive oil, groundnut oil, rapeseed oil,sunflower oil, palm oil, coconut oil, peanut oil, fish oil, and amixture thereof.

In a further preferred embodiment, the binder is chosen from amongpolyvinyl alcohol polymers, polyvinylpyrrolidone, the copolymers ofvinylpyrrolidone and vinyl acetate, maltodextrin,carboxymethylcellulose, its salts and derivatives, alginic aid and itssalts, zein, pectins, arabic gum, acacia gum, tragacanth gum, karayagum, xanthan gum, guar gum, carrageenans, gelatin, pullulan polymers,agar polymers, starches and their derivatives, carbomers, acrylic acidcross-linked with polyalkenyl ethers, polycarbophils, and a mixturethereof. In a more preferred embodiment, the binder is chosen from amongmaltodextrin, pregelatinized starch, xanthan gum, guar gum, and amixture thereof.

In a further preferred embodiment, the lubricant is chosen from amongpolyethylene glycol, magnesium or calcium stearate, stearic acid,vegetable oil, hydrogenated glyceryl palmitostearate, sodium stearylfumarate, and a mixture thereof, preferably polyethylene glycol 6000,magnesium stearate, stearic acid, and a mixture thereof.

In a further preferred embodiment, the filler is chosen from amongmaltodextrin, cyclodextrin, lactose, talc, silica, silicates,phosphates, cellulose, cellulose powder, microcrystalline cellulose,croscarmellose, mica, carbonates, sugar (polysaccharides), and a mixturethereof. In a more preferred embodiment, the filler is chosen from amongcellulose, microcrystalline cellulose, lactose, sugar, and a mixturethereof.

In a further preferred embodiment, the disintegrant is croscarmellose,crosspovidone, starch, sodium starch glycolate and a mixture thereof.

The solid compositions or “soft tablets” of the invention may furthercomprise any other excipients such as those described above. Forinstance, the “soft tablets” may further comprise at least onepreservative, at least one antioxidant, at least one chelating agent, atleast one coloring agent, and/or at least one pH regulator.

In a preferred embodiment, the preservative is chosen from amongparabens, benzoic acid, sodium benzoate, sorbic acid, potassium sorbate,and a mixture thereof.

In a further preferred embodiment, the antioxidant is chosen from amongascorbic acid, its salts and derivatives, sodium or potassiummetabisulphite, sodium bisulphite, butylhydroxyanisole,butylhydroxytoluene, gallic acid and its derivatives such as propylgallate, and a mixture thereof.

In a further preferred embodiment, the chelating agent is chosen fromamong EDTA and its salts, tartaric acid and its salts, and a mixturethereof.

In a further preferred embodiment, the at least one coloring agent ischosen from among iron oxides, titanium oxides, curcumin, caramel,carotenes, and a mixture thereof.

In a further preferred embodiment, the pH regulator is chosen from amongcitric acid, its salts and derivatives, sodium carbonates, delta gluconolactone, and a mixture thereof.

It will be understood that the excipients as described above may haveseveral functions. For instance, polyethylene glycol may be both ahumectant and a lubricant, sugar may be both a palatable material and afiller, croscarmellose may be both a filler and a disintegrant, etc.

In a more preferred embodiment, the “soft tablet” comprises milbemycin,milbemycin oxyme, both milbemycin oxyme and praziquantel, praziquantel,lufenuron, ivermectin, both ivermectin and pyrantel pamoate, lufenuron,levamizole, doxycycline or a dog appeasing pheromone, a palatablematerial chosen from among pig liver powder, chicken liver flavor,chicken flavor and yeasts, a humectant chosen from among propyleneglycol, glycerin, sorbitol, polyethylene glycol, soya bean oil, andpeanut oil, a binder chosen from among maltodextrin, pregelatinizedstarch, xanthan gum, and guar gum, a lubricant chosen from amongpolyethylene glycol 6000, magnesium stearate, and stearic acid, a fillerchosen from among sugar, cellulose, and lactose, and a croscarmellose asdisintegrant.

In a further more preferred embodiment, the solid composition or “softtablet” comprises: between 0.01 and 20.00%, preferably between 1.00 and10.00% by weight of said at least one active ingredient, between 15.00and 30.00%, preferably about 20.00% by weight of said at least onepalatable material, between 15.00 and 35.00%, preferably between 20.00and 30.00% by weight of said at least one humectant, between 20.00 and40.00%, preferably about 24.50% by weight of said at least one binder,between 0.10 and 10.00%, preferably about 5.00% by weight of said atleast one lubricant, between 10.00 and 30.00%, preferably between 15.00to 25.00% by weight of said at least one filler, and between 0.10 and10.00%, preferably about 4.0% by weight of said at least onedisintegrant, relative to the total weight of the solid composition.

As used herein, the term “about” will be understood by a person ofordinary skill in the art and will vary to some extent on the context inwhich it is used. If there are uses of the term which are not clear topersons of ordinary skill in the art given the context in which it isused, “about” will mean up to plus or minus 20%, preferably 10% of theparticular term.

As used herein, an “animal” comprises, without limitation, birds such ascanaries, finches, lovebirds, caiques and cockatoos, and non-humanmammal such as canidae, for instance dogs, foxes, coyotes, and wolfs,felidae, for instance cats, lions, and panthers, bovidae, for instancecattle and dairy cow, equidae, for instance horses, and camelidae, forinstance camel. In a particular embodiment, the animal is a companionanimal, preferably a dog or a cat, preferably a dog.

Process

The process for preparing a solid composition or a “soft tablet” asdisclosed herein comprises i) a granulation step, ii) a let standingstep of the granules, iii) a compression step, and iv) a collectingstep. More particularly, the process comprises the following successivesteps:

-   -   i) mixing said at least one active ingredient and said at least        one excipient in a granulator to obtain wet granules;    -   ii) spreading the obtained wet granules on a tray and let stand        for 2 to 24 hours between 15 and 25° C.;    -   iii) compressing granules obtained after step ii) with a tablet        press; and    -   iv) collecting the solid composition.

In a preferred embodiment, the granulation step i) is performed in twotimes and comprises a first step i) a) in which the powder ingredientsincluding said at least one active ingredient, said at least onepalatable material, said at least one binder, said at least one filler,said at least one lubricant, said at least one disintegrant are firstmixed in a granulator, and a second step i) b) in which said at leastone humectant, including oil humectant are sprayed onto the blend ofstep i) a) and then mixed to obtain wet granules.

Optionally, the powder ingredients may be sieved prior the granulationstep.

The at least one active ingredient may be added as a powder, asgranulates or coated granulates, complexed with maltodextrin orcyclodextrin, or in a liquid form.

The let standing step ii) consisting to spread the wet granules on atray and let stand or wait for 2 to 24 hours at room temperature, i.e.between 15 and 25° C., allows the liquids ingredients to be absorbedinto the granules, thereby providing the specific physical properties ofthe “soft” tablets obtained by such process. The temperature should inany case not be greater than 25 to 30° C. in order to prevent generatinga very sticky paste. The implementation of a process including steps i),iii), followed by a molding step i.e. without implementing step ii),will automatically provide classic soft chew, which are softer, morefriable, and wherein the active ingredient is less accurately dispersed,compared to the “soft tablets” of the invention.

In the context of the present invention, the sense of the term “tray” isnot limitative and include any device for which wet granules can be letstand at room temperature. For instance, wet granules can be let standat room temperature on a bench, a table, a box, or a plate. . .

In a preferred embodiment, the granules after let standing step ii) aremilled with an oscillating granulator, and then sifted, preferablythrough a 800 to 2000 μm sieve, preferably a 1250 μm sieve (Step ii)b)). Optionally, the granules are then let stand for 2 to 24 hours atroom temperature (Step ii) c)).

The compression step iii) is performed using a classic tablet press,i.e. with classic tooling, especially in the pharmaceutical orveterinary field. Indeed, the granules obtained after step ii) or stepii) b) or ii) c) are quite hardened and solid to be used in a presscurrently used for the manufacture of conventional tablets. Thus, thecompression step does not require a specific machine to compress thegranules, which is very important from a scale-up and economicalprocess. The shape of the “soft tablets” of the invention depends on themold used for the compression step and the breakability in a bi- orquadrisection depends on the punch used.

Optionally, the process comprises a step iii) a) of blending thegranules with at least one disintegrant and/or at least one filler in ablender before the compression step. In a particular embodiment, theprocess further comprises a step iii) b) of blending the granules withat least one lubricant in a blender.

Therefore, a more preferred embodiment of the invention is a processcomprising the following successive steps:

-   -   i) a) mixing said at least one active ingredient, said at least        one palatable material, said at least one binder, said at least        one filler, said at least one lubricant, and said at least one        disintegrant in a granulator;    -   i) b) spraying said at least one humectant onto the blend of        step i) a) and mixing to obtain wet granules;    -   ii) a) spreading the wet granules obtained after step i) b) on a        tray and let stand for 2 to 24 hours between 15 and 25° C.;    -   ii) b) milling the granules obtained after step ii) a) with an        oscillating granulator, and then sifted, preferably through a        800 to 2000 μm sieve, preferably through a 1250 μm sieve;    -   ii) c) optionally let standing the granules for 2 to 24 hours at        room temperature;    -   iii) a) optionally blending the granules obtained after        step ii) b) or step ii) c) with at least one disintegrant and/or        at least one filler in a blender;    -   iii) b) blending the granules obtained after step ii) b), ii) c)        or iii) a) with at least one lubricant in a blender;    -   iii) c) compressing the blend obtained after step iii) b) with a        tablet press; and    -   iv) collecting the solid composition.

Particularly, the granule obtained after let standing step ii), andoptionally after milling step ii) b) with an oscillating granulatorthrough a 800 to 2000 μm sieve, and optionally after let standing stepii) c) comprises:

-   -   said at least one active ingredient in a range between 0.01 and        20.00%, preferably between 1.00 and 10.00% by weight,    -   said at least one palatable material in a range between 15.00        and 30.00%, preferably about 20.00% by weight,    -   said at least one humectant in a range between 15.00 and 35.00%,        preferably between 20.00 and 35.00% by weight,    -   said at least one binder in a range between 20.00 and 40.00%,        preferably about 24.50% by weight,    -   said at least one lubricant in a range between 0.01 and 10.00%,        preferably between 0.10 and 5.00% by weight,    -   said at least one filler in a range between 0.10 and 20.00%, and    -   said at least one disintegrant in a range between 0.10 and        10.00%, preferably about 4.00% by weight, relative to the total        weight of the granule.

Particularly, the solid composition or “soft tablet” comprises:

-   -   said granule obtained after the let standing step ii), and        optionally after the milling step ii) b) and ii) c), in a range        between 83.50 and 99.98%, preferably about 90.75% by weight,    -   said at least one filler, preferably cellulose, lactose, sugar,        croscarmellose, and a mixture thereof in a range between 0.01        and 15.00%, preferably about 7.50% by weight, and    -   said lubricant, preferably magnesium stearate, stearic acid, and        a mixture thereof, in a range between 0.01 and 2.50%, preferably        about 1.75% by weight, relative to the total weight of the solid        composition.

More particularly, the solid composition or “soft tablet” comprises:

-   -   between 0.01 and 20.00%, preferably between 1.00 and 10.00% by        weight of said at least one active ingredient,    -   between 15.00 and 30.00%, preferably about 20.00% by weight of        said at least one palatable material,    -   between 15.00 and 35.00%, preferably between 20.00 and 30.00% by        weight of said at least one humectant,    -   between 20.00 and 40.00%, preferably about 24.50% by weight of        said at least one binder,    -   between 0.10 and 10.00%, preferably about 5.00% by weight of        said at least one lubricant,    -   between 10.00 and 30.00%, preferably between 15.00 and 25.00% by        weight of said at least one filler, and    -   between 0.10 and 10.00%, preferably about 4.00% by weight of        said at least one disintegrant, relative to the total weight of        the solid composition.

Further aspects and advantages of the invention will be disclosed in thefollowing experimental section. The examples below illustrate thepresent invention and are given as non-limiting illustrations.

EXAMPLES Example 1: Process to Manufacture a Soft Tablet Comprising(Doxycycline)

In a granulator, all powder ingredients are mixed together in theamounts specified below:

Doxycycline hyclate 23.08 g Yeast extract 52.95 g Chicken flavor 12.46 gMaltodextrin 43.26 g Pregelatinized starch 37.37 g Guar gum 3.27 gXanthan gum 1.40 g Dextrose 26.47 g Microcrystalline cellulose 17.13 gCroscarmellose 14.02 g PEG 6000 6.23 g

Then, humectants are sprayed onto the blend (sorbitol 30.21 g andglycerin 26.47 g premixed together) followed by the oily humectant soyaoil (20.24 g). The resulting material is mixed to generate wet granules.

The wet granules are then spread on tray and left standing for 24 hoursat a temperature of about 20° C.

The granules are then milled with an oscillating granulator through a1250 μm sieve

Granules were spread and left at ambient temperature for 6 hours.

The resulting granules were first blended in a blender with 17.27 g ofmicrocrystalline cellulose, followed by addition of 6.80 g of stearicacid, and 1.36 g of magnesium stearate.

The granules were then compressed in a tablet press into tablets calledsoft tabs.

Tablets of 340 mg and 1530 mg were produced. 340 mg soft tabletscontaining 20 mg doxycycline were oblong with a punch size of 12.7 mmwhile 1530 mg soft tablets containing 90 mg doxycycline were round witha punch size of 16 mm.

The resulting tablet composition contains the following components:

Ingredient Product WT % Active ingredient Doxycycline hyclate 6.79Palatable material Yeast extract 15.57 Chicken flavor 3.66 BinderMaltodextrin 12.38 Pregelatinized starch 10.99 Guar gum 0.96 Xanthan gum0.41 Humectant Soya oil 5.95 Glycerin 7.79 Sorbitol 8.89 Filler Dextrose7.79 Microcrystalline cellulose 10.47 Disintegrant Croscarmellose 4.12Lubricant PEG 6000 1.83 Stearic acid 2.00 Magnesium stearate 0.40

Furthermore, the tablet produced in Example 1 has no measurablehardness. Hardness is the force required to break a tablet, (expressedin Kg). Hardness of these soft tablets according to this example cannotbe measured as the tablet bends upon applying pressure.

Friability is defined as the % of weight loss by tablets due tomechanical action during a conventional tumbler test. 20 tablets wereplaced in a tumbler and exposed to rolling and repeated shocks as theyfall 6 inches in each turn within the apparatus. After 4 minutes of thistreatment (100 revolutions) the tablet were weighed and the weightcompared with the initial weight. Since the weight was not changed,measured friability was.

Secability of the ½ and ¼ tablets produced according to the inventionwere in conformity with the pharmacopoeia 0478 2.9.5.

Example 2: Soft Tablet Composition Comprising Milbemycin andPraziquantel

In a granulator, all powder ingredients are mixed together in theamounts specified below:

Milbemycin 4 g Praziquantel 10 g Malted yeast 52.94 g Chicken flavor10.90 g Maltodextrin 39.87 g Pregelatinized starch 43.60 g Guar gum 3.27g Xanthan gum 1.40 g Dextrose 31.14 g Microcrystalline cellulose 18.68 gCroscarmellose 14.01 g PEG 6000 6.23 g

Then, humectants are sprayed onto the blend (sorbitol 30.21 g andglycerin 24.91 g premixed together) followed by the oily humectant soyaoil (20.24 g). The resulting material is mixed to generate wet granules.

The wet granules are then spread on tray and left standing for 24 hoursat a temperature of about 20° C.

The granules are then milled with an oscillating granulator through a1250 μm sieve

Granules were spread and left at ambient temperature for 6 hours.

The resulting granules were first blended in a blender with 20.40 g ofmicrocrystalline cellulose, followed by addition of 6.80 g of stearicacid, and 1.36 g of magnesium stearate.

The granules were then compressed in a tablet press into tablets.

Tablets of 340 mg were produced containing 4 mg mylbemycin and 16 mgpraziquantel. These tablets were oblong with a punch size of 12.7 mm.

The resulting tablet composition contains the following components:

Ingredient Product WT % Active ingredient Milbemycin 1.18 Praziquantel2.94 Palatable material Malted yeast 15.57 Chicken flavor 3.21 BinderMaltodextrin 11.74 Pregelatinized starch 12.82 Guar gum 0.96 Xanthan gum0.41 Humectant Soya oil 5.95 Glycerin 7.33 Sorbitol 8.88 Filler Dextrose9.16 Microcrystalline cellulose 11.50 Disintegrant Croscarmellose 4.12Lubricant PEG 6000 1.83 Stearic acid 2.00 Magnesium stearate 0.40

1. A process for preparing a solid soft tablet composition comprising atleast one active ingredient, at least one excipient, and a humectant ata concentration between 15.00% and 35.00% by weight, relative to thetotal weight of the solid soft tablet composition, wherein the processcomprises the following steps: i) mixing said at least one activeingredient, said at least one excipient, and said humectant in agranulator to obtain wet granules; ii) spreading the wet granules andletting stand for 2 to 24 hours between 15 and 25° C.; iii) compressingthe granules obtained after step ii) with a tablet press; and iv)collecting a solid soft tablet composition, wherein the solid softtablet composition is not sticky, is not friable and is hard enough tobe manipulated and packaged.
 2. The process according to claim 1,wherein the at least one active ingredient is selected from the groupconsisting of anti-infectives, antibiotics and sulfonamides,cardiotonics, internal and external anti-parasitics, insecticides,insect growth inhibitors, anti-arthritics, anti-inflammatories whetheror not steroidal, anti-histaminics, hormones, gastro-intestinaldressings and sedatives, anti-ulcer agents and substitution flora,anti-diarrhoeals, hepato-protectors, antispasmodics, laxatives,intestinal antiseptics, respiratory analeptics, antitussives,bronchodilators, bronchial and mucolytic fluidifiers and respiratoryantiseptics, analgesics, sedatives and tranquilizers, anti-epileptics,anaesthetics, orexigenics, anorexigenics, interleukins and interferon,antimitotics and cytostatics, macro-, micro-nutrients and traceelements, vitamins, plant extracts, extracts from animal organs, and amixture thereof.
 3. The process according to claim 1, wherein the atleast one active ingredient is an active nutraceutical ingredient or afood supplement ingredient, selected from the group consisting of plantextracts, animal extracts, substitution flora, macro-nutrients,micro-nutrients and trace-elements, and a mixture thereof.
 4. Theprocess according to claim 1, wherein the at least one excipient isselected from the group consisting of a palatable material, a binder, alubricant, a filler, a disintegrant, and a mixture thereof.
 5. Theprocess according to claim 1, wherein said at least one excipient is apalatable material selected from the group consisting of meat, meatpowders, fish powders, cheese powders, milk derivatives, liver powder,yeasts, yeast extracts, vegetable fibers, malt extract, fenugreek,apple, carrot, fodder beet, sugar beet, thyme, alfalfa, sugar cane,cereals, their flours and a mixture thereof, crystallized sugar, powdersugar glucose, invert sugar, molasses, caramel, honey and itsderivatives, sodium chloride, and a mixture thereof.
 6. The processaccording to claim 1, wherein said at least one excipient is a palatablematerial selected from the group consisting of a pig liver powder, achicken liver flavor, a chicken flavor, yeast extract, malt extract, anda mixture thereof.
 7. The process according to claim 1, wherein said atleast one excipient is a binder selected from the group consisting ofpolyvinyl alcohol polymers, polyvinylpyrrolidone, the copolymers ofvinylpyrrolidone and vinyl acetate, maltodextrin, carboxymethylcelluloseand salts and derivatives thereof, alginic acid and its salts, zein,pectins, arabic gum, acacia gum, gum tragacanth, karaya gum, xanthangum, guar gum, carrageenans, gelatin, pullulan polymers, agar polymers,starches and their derivatives, acrylic acid cross-linked withpolyalkenyl ethers and a mixture thereof.
 8. The process according toclaim 1, wherein said at least one excipient is a lubricant selectedfrom the group consisting of polyethylene glycol, magnesium or calciumstearate, stearic acid, vegetable oil, hydrogenated glycerylpalmitostearate, sodium stearyl fumarate, and a mixture thereof.
 9. Theprocess according to claim 1, wherein said at least one excipient is afiller selected from the group consisting of maltodextrin, cyclodextrin,lactose, talc, silica, silicates, phosphates, cellulose, cellulosepowder, microcrystalline cellulose, croscarmellose, mica, carbonates,sugar, and a mixture thereof.
 10. The process according to claim 1,wherein said at least one excipient is a disintegrant selected from thegroup consisting of croscarmellose, crosspovidone, starch, sodium starchglycolate and a mixture thereof.
 11. The process according to claim 1,wherein the collected solid soft tablet further comprises at least onepreservative selected from the group consisting of parabens, benzoicacid, sodium benzoate, sorbic acid, potassium sorbate, and a mixturethereof, and/or at least one antioxidant selected from the groupconsisting of ascorbic acid, its salts and derivatives, sodium orpotassium metabisulphite, sodium bisulphite, butylhydroxyanisole,butylhydroxytoluene, gallic acid and its derivatives, and a mixturethereof, and/or at least one chelating agent selected from the groupconsisting of EDTA and its salts, tartaric acid and its salts, and amixture thereof.
 12. The process according to claim 1, comprising thefollowing steps: i) a) mixing the at least one active ingredient, the atleast one palatable material, at least one binder, the at least onefiller, the at least one lubricant, and the at least one disintegrant ina granulator to form a blend; i) b) spraying the humectant onto theblend of step i) a) and mixing to obtain wet granules; ii) a) spreadingthe wet granules obtained after step i) b) and letting stand for 2 to 24hours between 15 and 25° C.; ii) b) milling the granules obtained afterstep ii) a) with an oscillating granulator, and then sifting through an800 to 2000 μm sieve; ii) c) optionally letting the milled granulesobtained after step ii) b) stand for 2 to 24 hours at room temperature;iii) a) optionally blending the milled granules obtained after step ii)b) or step ii) c) with at least one disintegrant and/or at least onefiller in a blender; iii) b) blending the granules obtained after stepii) b), ii) c) or iii) a) with at least one lubricant in a blender; iii)c) compressing the blend obtained after step iii) b) with a tabletpress; and iv) collecting the solid soft tablet composition.
 13. Theprocess according to claim 1, wherein the collected solid soft tabletcomposition comprises: between 0.01 and 20.00% by weight of said atleast one active ingredient, between 15.00 and 30.00% by weight of atleast one palatable material, between 20.00 and 40.00% by weight of atleast one binder, between 0.10 and 10.00% by weight of at least onelubricant, between 10.00 and 30.00% by weight of at least one filler,and between 0.10 and 10.00% by weight of at least one disintegrant,relative to the total weight of the collected solid soft tabletcomposition.
 14. The process according to claim 1, wherein said at leastone excipient is a binder selected from the group consisting ofmaltodextrin, pregelatinized starch, xanthan gum, guar gum, and amixture thereof.
 15. The process according to claim 1, wherein said atleast one excipient is a lubricant selected from the group consisting ofpolyethylene glycol 6000, magnesium stearate, stearic acid, and amixture thereof.
 16. The process according to claim 1, wherein said atleast one excipient is a filler selected from the group consisting ofcellulose, microcrystalline cellulose, lactose, sugar, and a mixturethereof.